Lipid ProfileNCT07419074
Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients
A study testing Garcinia cambogia rind powder in people with Lipid Profile, run by University of Lahore at 1 site in Pakistan.
Trial summary
Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited. Read more about this study
- Who is it for?
- Ages 30 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Lipid Profile
- What is being tested?
- Garcinia cambogia rind powder
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Sep 2025to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Participants of both genders were included if they were aged 30-60 years,
- body mass index (BMI) ≥30 kg/m²,
- Individuals with HbA1c levels ranging from 5.7% to 10% were selected, .indicating pre-diabetic to diabetic status. Participants were required to have a .body mass index (BMI) of 25 kg/m² or higher
Who cannot join
- Participants who were diagnosed with type 1, pregnant or lactating,
- chronic liver, kidney, or cardiovascular disease,
- history of hepatotoxicity or gastrointestinal disorders,
- using weight-loss supplements, steroids, or lipid-lowering drugs, or had a known allergy to Garcinia cambogia
Trial locations and contacts
1 site in 1 country.
About this study
Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.
Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.
Read the detailed description
The observed effects are likely mediated by HCA, which inhibits ATP-citrate lyase, reducing de novo lipogenesis, enhancing glucose utilization, and modulating adipokines and oxidative stress.
Conclusion: Garcinia cambogia rind powder supplementation exerts dose-dependent metabolic benefits in pre-diabetic obese adults, improving anthropometric, glycemic, lipid, hepatic, and renal parameters without adverse effects. It may serve as a complementary intervention alongside lifestyle modification for the management of obesity and pre-diabetes.
- Conditions
- Lipid Profile
- Being tested
- Garcinia cambogia rind powder
- Keywords
- Garcinia cambogia, Garcinia gummi-gutta, hypoglycemic effect, pre-diabetic, obesity, hydroxycitric acid (HCA), glucose metabolism
- Medical subject headings
- Glucose Intolerance, Obesity, Adenoma, Liver Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Garcinia cambogia rind powderDietary supplement
Once a day
Garcinia cambogia rind powderDietary supplement
Once a day for 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Placebo group | Placebo comparator | Starch capsule once a day Receives: Dietary Supplement: Garcinia cambogia rind powder |
| T1 | Experimental | 100mg/day of Garcinia cambogia rind powder Receives: Dietary Supplement: Garcinia cambogia rind powder |
| T2 | Experimental | 200mg/day of Garcinia cambogia rind powder Receives: Dietary Supplement: Garcinia cambogia rind powder |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight
Measured: 12 weeks
Secondary outcomes (2)
Lipid profile
Measured: 12 weeks
fasting glucose
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start1 Sep 2025
- Primary completion24 Nov 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lipid ProfileStudies of the same condition, open and under way.
- More trials run by University of LahoreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Lahore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07419074
- Sponsor's protocol ID
- UOL/IREB/25/12/0053
- Status last verified
- Oct 2025
- First submitted
- 11 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients
- ClinicalTrials.gov ID
- NCT07419074
- Acronym / sponsor ID
- UOL/IREB/25/12/0053
- Conditions
- Lipid Profile
- Keywords
- Garcinia cambogia, Garcinia gummi-gutta, hypoglycemic effect, pre-diabetic, obesity, hydroxycitric acid (HCA), glucose metabolism
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- University of LahoreUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 24 Nov 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.
Objective: To evaluate the effects of Garcinia cambogia rind powder supplementation on anthropometric, glycemic, lipid, hepatic, and renal parameters in pre-diabetic obese adults.
Detailed description
The observed effects are likely mediated by HCA, which inhibits ATP-citrate lyase, reducing de novo lipogenesis, enhancing glucose utilization, and modulating adipokines and oxidative stress.
Conclusion: Garcinia cambogia rind powder supplementation exerts dose-dependent metabolic benefits in pre-diabetic obese adults, improving anthropometric, glycemic, lipid, hepatic, and renal parameters without adverse effects. It may serve as a complementary intervention alongside lifestyle modification for the management of obesity and pre-diabetes.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo group | Placebo comparator | Dietary Supplement: Garcinia cambogia rind powderStarch capsule once a day |
| T1 | Experimental | Dietary Supplement: Garcinia cambogia rind powder100mg/day of Garcinia cambogia rind powder |
| T2 | Experimental | Dietary Supplement: Garcinia cambogia rind powder200mg/day of Garcinia cambogia rind powder |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Participants of both genders were included if they were aged 30-60 years,
- body mass index (BMI) ≥30 kg/m²,
- Individuals with HbA1c levels ranging from 5.7% to 10% were selected, .indicating pre-diabetic to diabetic status. Participants were required to have a .body mass index (BMI) of 25 kg/m² or higher
Key exclusion criteria (4 listed)
- Participants who were diagnosed with type 1, pregnant or lactating,
- chronic liver, kidney, or cardiovascular disease,
- history of hepatotoxicity or gastrointestinal disorders,
- using weight-loss supplements, steroids, or lipid-lowering drugs, or had a known allergy to Garcinia cambogia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Garcinia cambogia rind powderOnce a day | Dietary supplement | Placebo group |
| Garcinia cambogia rind powderOnce a day for 12 weeks | Dietary supplement | T1, T2 |
Primary outcome
Weight
Time frame: 12 weeks
2 secondary outcomes
Lipid profile
Time frame: 12 weeks
fasting glucose
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Randomized trial on weight and lipid profile of obese by formulation from Garcinia cambogiaLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Lipid Profile
Not yet recruiting
Prickly Pear Pulp Powder Along With an Anti-inflammatory Diet in Patients Having Liver Fibrosis
Lipid Profile, Blood Glucose
Active, not recruitingObservational study
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Recruiting
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
Prediabetes, Lipid Profile
Recruiting
Acute Effects of MCT Formulations on Beta-Hydroxybutyrate Response, Lipid Profile, and Glucose Levels in Healthy Adults
Ketone Body, Lipid Metabolism
RecruitingPhase 2
Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes
Diabetes Mellitus, Type 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Garcinia cambogia rind powder in people with Lipid Profile, run by University of Lahore at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.